Speaker Profile
M.D., Professor, Rutgers Cancer Inst.
Biography
Dr. Hinrichs is a physician-scientist who has pioneered cell therapy for HPV-associated and other epithelial cancers. He discovered tumor-infiltrating lymphocyte therapy for HPV-associated cancers, the first cell therapy to produce durable complete responses in epithelial cancers. He also discovered gene-engineered TCR-T cell therapies targeting HPV antigens and demonstrated their safety and clinical activity. His laboratory focuses on T-cell receptor discovery, next-generation cell therapies, and mechanisms of response to immunotherapy. At Rutgers Cancer Institute, he leads a bench-to-bedside-and-back cell therapy program that uses the Cell Therapy Research Laboratory, Process Development Laboratory, and GMP Facility to bring new treatments to patients in New Jersey. Clinical trials with on-site GMP manufacturing include therapies for gastric, lung, breast, cervical, oropharyngeal, anal, and other genital cancers.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Priti Hegde, Kite Pharma
PMWC Award Ceremony
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: The Industrialization of Cell Therapy:From Autologous Pioneers to Allogeneic Frontiers
• Arie S. Belldegrun, Allogene Therapeutics
Next Generation CAR-T Cell Therapies: Expanding Targets and Enhancing Designs
• Chair: Erin Harris Cell & Gene
• David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia University
PMWC Award Ceremony
• Michel Sadelain, Columbia University
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia University
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford University
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Stanford
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• Zach Roberts, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Priti Hegde, Kite Pharma
Smart Scaling: Leverating AI & Automation to De-Risk Advanced Therapy Manufacturing
• Chair: Stacie Calad-Thomson
• Samuel Rodriques, FutureHouse
• Manuel Leonetti, Biohub
• Fabian Gerlinghaus, Cellares
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
In Vivo CAR Therapy: Immune Reprogramming Directly in Patients
• Daniel Getts, Myloid Therapeutics
Operationalizing Cell & Gene Therapy Trials in a Large Health System
•Snehit Prabhu, Stanford
Gene Editing & Synthetic Biology for Therapy
• Chair: Trevor Martin, Mammoth Biosciences
• Ken Drazan, ArsenalBio
• Lynn Seely, Lyell
• Kole T. Roybal, Parker Institute
• David Kirn, 4DMT
